Publication:
Review article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk

dc.contributor.authorYILMAZ, YUSUF
dc.contributor.authorsYilmaz, Y.
dc.date.accessioned2022-03-10T11:39:58Z
dc.date.accessioned2026-01-11T08:03:14Z
dc.date.available2022-03-10T11:39:58Z
dc.date.issued2012-08
dc.description.abstractBackground Low bone mineral density (BMD) has been reported in both paediatric and adult patients with non-alcoholic fatty liver disease (NAFLD). The mechanisms behind the reduced BMD in NAFLD are still not completely understood. Aim To provide a critical overview of the pathophysiological pathways linking NAFLD, reduced BMD and osteoporosis, with a special focus on the alterations of soluble mediators which could link fat accumulation in the liver with bone health. The MEDLINE database was searched by a combination of keywords: non-alcoholic fatty liver disease OR hepatic steatosis OR metabolic syndrome OR insulin resistance AND bone mineral density OR osteoporosis OR bone AND biomarkers OR serum marker. Results Several factors that may influence bone mineralisation and the increased risk of osteoporosis in NAFLD can be discussed. These include the release of cytokines from the inflamed liver which may influence the bone microenvironment, vitamin D deficiency, and limited physical activity. Circulating markers of bone metabolism, including osteopontin, osteoprotegerin, osteocalcin and fetuin-A, have been found to be altered in patients with NAFLD. Conclusion A better understanding of the mechanisms that link bone metabolism and the liver may open a new frontier to fight two highly prevalent conditions like NAFLD and osteoporosis.
dc.identifier.doi10.1111/j.1365-2036.2012.05196.x
dc.identifier.eissn1365-2036
dc.identifier.issn0269-2813
dc.identifier.pubmed22730920
dc.identifier.urihttps://hdl.handle.net/11424/219943
dc.identifier.wosWOS:000306406200004
dc.language.isoeng
dc.publisherWILEY
dc.relation.ispartofALIMENTARY PHARMACOLOGY & THERAPEUTICS
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBONE-MINERAL DENSITY
dc.subjectNECROSIS-FACTOR-ALPHA
dc.subjectINFLAMMATORY-BOWEL-DISEASE
dc.subjectSERUM OSTEOCALCIN LEVELS
dc.subjectVITAMIN-D
dc.subjectMETABOLIC SYNDROME
dc.subjectFETUIN-A
dc.subjectCIRCULATING OSTEOPROTEGERIN
dc.subjectINSULIN SENSITIVITY
dc.subjectRECEPTOR ACTIVATOR
dc.titleReview article: non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk
dc.typereview
dspace.entity.typePublication
oaire.citation.endPage352
oaire.citation.issue4
oaire.citation.startPage345
oaire.citation.titleALIMENTARY PHARMACOLOGY & THERAPEUTICS
oaire.citation.volume36

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
112.62 KB
Format:
Adobe Portable Document Format